Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TransMedics (TMDX) EBITDA Margin (2018 - 2025)

Historic EBITDA Margin for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to 16.2%.

  • TransMedics' EBITDA Margin rose 125900.0% to 16.2% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.94%, marking a year-over-year increase of 91000.0%. This contributed to the annual value of 8.49% for FY2024, which is 203800.0% up from last year.
  • Per TransMedics' latest filing, its EBITDA Margin stood at 16.2% for Q3 2025, which was up 125900.0% from 23.24% recorded in Q2 2025.
  • Over the past 5 years, TransMedics' EBITDA Margin peaked at 23.24% during Q2 2025, and registered a low of 216.61% during Q3 2021.
  • Its 5-year average for EBITDA Margin is 34.27%, with a median of 5.03% in 2023.
  • Per our database at Business Quant, TransMedics' EBITDA Margin plummeted by -1587900bps in 2021 and then surged by 1950200bps in 2022.
  • TransMedics' EBITDA Margin (Quarter) stood at 132.57% in 2021, then skyrocketed by 84bps to 21.61% in 2022, then soared by 115bps to 3.21% in 2023, then skyrocketed by 122bps to 7.11% in 2024, then surged by 128bps to 16.2% in 2025.
  • Its EBITDA Margin stands at 16.2% for Q3 2025, versus 23.24% for Q2 2025 and 19.12% for Q1 2025.